Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
Top Cited Papers
- 1 July 2011
- journal article
- webcast
- Published by Elsevier in Gastroenterology
- Vol. 141 (1), 150-156
- https://doi.org/10.1053/j.gastro.2011.02.018
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodentsAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or SitagliptinDiabetes Care, 2010
- Antimicrobials and the Risk of Torsades de PointesDrug Safety, 2010
- Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and BenefitsDiabetes Care, 2010
- Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?Diabetologia, 2009
- Antidiabetic Therapies Affect Risk of Pancreatic CancerGastroenterology, 2009
- Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 DiabetesDiabetes, 2009
- Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysisBMC Endocrine Disorders, 2008
- Incretin-Based Therapies in Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2008
- Rosiglitazone and Risk of CancerDiabetes Care, 2008